PropThink: Five More Years of Patent Protection, and Revenue, for Spectrum Pharmaceuticals

PropThink: Five More Years of Patent Protection, and Revenue, for Spectrum Pharmaceuticals

[ACN Newswire] – By Jake KingSpectrum Pharmaceuticals (NASDAQ:SPPI) announced Monday morning that the company received a five-year extension on its patent for Folotyn, which lengthens the drug’s market exclusivity from … more

View todays social media effects on SPPI

View the latest stocks trending across Twitter. Click to view dashboard

Share this post